Everything you need to know about Non-specialty pipeline from 4/2010 through 9/2010

[chantell.reagan]

DETAILS:

Please click on the product name to view up-to-date details captured by DrugPipelineForecast

Antiinfectives:
Expected approvals in 2Q2010

o Oravig (previously known as Loramyc) - FDA approved 4/10

Cardiovascular:
Expected approvals in 2Q2010

o Axanum - Complete response letter received

Expected approvals in 3Q 2010

o Brilinta - FDA advisory board recommends drug 7/10

CNS:
Expected approvals in 2Q2010

o Abstral (no recent updates)
o PecFent
o Sprix - FDA approved 5/10
o Stedesa - Complete response letter received
o Vimovo – FDA approved 5/10

Expected approvals in 3Q2010

oAricept 23 mg - FDA approved 7/10
oClonicel
oDyloject - PDUFA date 10/3/10
onaproxcinod-PDUFA 7/24/10, Complete response letter received
oPotiga (retigabine) - FDA advisory board 8/10
osodium oxybate - FDA advisory board 8/10
oStaccato - PDUFA date 10/10

Dermatologicals:
Expected approvals in 3Q2010

o Rectogesic - Complete response letter received

Endocrine/diabetes:
Expected approvals in 3Q2010

o Bydureon - PDUFA 10/10
o Natazia - FDA approved 5/10

GI:
Expected approvals in 2Q2010

o MGX006 (no recent updates)

Respiratory:
Expected approvals in 2Q2010

o Daxas - FDA advisory board rejects drug 4/10
o Dulera - FDA approved 6/10

Latest updates are captured in the Non-Specialty Pipeline Forecast as of March 2010

For more information, longer-term pipeline, or to search for additional drugs, please see DrugPipelineForecast.

About DrugPipelineForecast:
DrugPipelineForecast is a tool developed specifically for managed care professionals to address their unique needs. This is a site which can help you track late-phase pipeline:

o Products in late phase III to approval stages
o All types of information for an in-depth review
o Tabulated format for a quick analysis
o Search and filtering capabilities
o Default and customized reports
o Frequent updates

To access DrugPipelineForecast at no charge (for those who are currently employed by a health plan, PBM, specialty pharmacy, IPA, employer/benefits consultant), you must be a registered user of DrugManagementForum (click here to register)

About DrugManagementForum:
DrugManagementForum is dedicated to the managed care pharmacy and medical policy community, allowing you to connect and share your ideas and solutions to common problems and experiences. It offers a place for users and experts to post questions and comments that are relevant to your practice in the managed care setting.

Benefits of registering with DrugManagementForum:

o Offers managed care professionals to connect and share ideas/solutions to common problems and experiences in drug benefit management
o Objective, unbiased content without a commercial agenda (no pharma sponsorship)
o Exclusive only for those who are currently employed by a health plan, PBM, specialty pharmacy, IPA, employer/benefits consultant, or another organization that is responsible for managing healthcare coverage (those in academia and benefit consulting can also join)
o Free and includes access to the DrugPipelineForecast
o Anonymity is guaranteed (if preferred), see the rules for more details